Life Sciences Tools and Services

Pharmaron

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

BlackRock Reduces Holdings in Kangbok Chemical's H Shares

Three Shareholders of Kanglong Chemical Plan to Reduce 1.57% Equity

Kanglong Chemical's Shareholders Plan to Sell Up to 1.50% Shares

CICC Raises Target Price for Kanghong Chemical to HKD 28

Pharmaron released FY2026 Q1 earnings on April 28 During-Market (BJT), actual revenue CNY 3.578 B (forecast CNY 3.542 B), actual EPS CNY 0.185 (forecast CNY 0.21)

JPMorgan Reduces Holding in Konica Minolta China to 21.05 Million Shares

Pharmaron to release FY2026 Q1 earnings report on April 28 During-Market (BJT), forecast revenue CNY 3.507 B, EPS CNY 0.21

Morgan Stanley Raises Target Price for Kanglong Chemical to HKD 31.5 and Gives an 'Overweight' Recommendation

CMBI Reiterates Buy Rating on Kangbok Chemical H Shares

Kanglong Chem 完成制剂车间建设并签订战略合作协议

Canlon Chemicals Reports Revenue Growth but Net Profit Decline in 2025

Pharmaron released FY2025 annual earnings on March 30 After-Market (BJT), actual revenue CNY 14.1 B (forecast CNY 14.05 B), actual EPS CNY 0.9393 (forecast CNY 0.9801)

Pharmaron released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 4.009 B (forecast CNY 3.981 B), actual EPS CNY 0.2916 (forecast CNY 0.28)

Kangbashi Establishes New Drug Production Company in Shaoxing

Pharmaron to Release FY2025 Earnings on March 30 After-Market (BJT), Forecast Revenue CNY 14.05 B, EPS CNY 0.9801

Norwegian Central Bank Buys Shares in Canbridge Pharma

JPMorgan Reduced Its Stake in ChemPartner to 5.94%

Citi Gives Kanghongcheng a Buy Rating and Positive Catalyst Observation

Norges Bank Sells 1,834,200 Shares of Kanglong Chemical

03759

300759

Goldman Sachs has reaffirmed its Buy rating for Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$29.70. The stock closed at HK$21.72 last Tuesday. The analyst consensus for Pharmaron is a Strong Buy, with a price target consensus of €3.18.

Tip Ranks

PHARMARON

Goldman Sachs

GS Hldg R

Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)

159892

513060

562050

159506

588130

520690

159992

512290

159849

BOCI has raised its target price for PHARMARONfrom HKD25 to HKD26, maintaining a Buy rating. The company reported a 15.5% YoY revenue increase to RMB3.58 billion in 1Q26, with adjusted net profit up 16.2% YoY. Newly signed orders rose over 30% YoY, driven by strong demand for laboratory services and small-molecule CDMO. BOCI also increased its revenue forecasts for 2026 and 2027 by 3.6% and 6.5%, respectively, citing faster project conversion. Despite trading at a discount compared to peers, PHARMARON's profitability is improving as CDMO contributions rise.

AASTOCKS News

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

WuXi AppTec

WUXI APPTEC

Asymchem

BOCI Raises PHARMARON  TP to HKD26, Maintains Buy

Today, Pharmaron continued its recent weak consolidation trend, with a trading volume of approximately HKD 341 million, and the trading activity was relatively light. However, on the daily MACD level, bullish signals have quietly emerged, with the DIF line beginning to converge with the DEA line and showing signs of a crossover. This typically indicates that the short-selling momentum accumulated during the previous continuous pullback is waning, increasing the likelihood of a phase stabilization. From the recent trend, Pharmaron's stock price has been oscillating in the low range for several trading days, with a clear characteristic of shrinking volume, indicating that selling pressure is gradually easing, but buying power has not yet significantly intervened. On the news front, the CXO industry is currently in a critical observation period for order recovery. Recent market news shows that the number of global innovative drug R&D pipelines continues to grow, and the outsourcing demand from large overseas pharmaceutical companies is rebounding, which is a medium to long-term positive for CRO companies like Pharmaron. Meanwhile, the Federal Reserve's decision to maintain interest rates has limited impact on the global biopharmaceutical financing environment, but Powell's hawkish statements have delayed market expectations for liquidity easing, and in the short term, the risk appetite for growth stocks remains cautious. The Hong Kong pharmaceutical sector has recently seen mixed performance, lacking a unified bullish force. From a technical perspective, Pharmaron's current stock price is operating near the short-term moving averages, and the continuous shrinkage in volume suggests that the market is waiting for a directional choice. If there is a moderate increase in volume in the following trading days and the stock can stabilize above the moving averages, the effectiveness of the bullish signals will significantly increase. It is important to note that the leading company in the CXO sector, WuXi AppTec, fell sharply by 3.7% today, and the sector's linkage effect may weigh on Pharmaron, so attention should be paid to whether the leading company stabilizes

Technical Forecast

Pre-market trend | Pharmaron (3759.HK) is consolidating with reduced volume on April 29, initial bullish signals are emerging, is it building up for a rebound or a trap for the bulls?

Pharmaron's stock price rose 8.61% today, closing at 20.44 yuan, with a trading volume of 9.5382 million shares. Nomura reported that Pharmaron's performance in the fourth quarter of last year met expectations, with revenue and profit increasing by 16% and 41%, respectively. It is expected that revenue will grow by 12% to 18% in 2026. Nomura raised the target price from 26.63 yuan to 27.33 yuan and maintained a "Buy" rating

AASTOCKS

Pharmaron rose over 8% in half a day, receiving a target price upgrade from Nomura

002821

002361

000550

The automotive vehicle sector showed strength, with the bus segment leading the gains. Yutong Bus and SG Automotive Group both hit the daily limit, while Zhongtong Bus Holding Co.,LTD, KLM, JMC, and Ankai saw significant increases. The commercial aerospace concept continued its strong performance, with SHENJIAN GUFEN up for 4 consecutive trading days, followed by SHUNHO STOCK, Shaoyang Hydraulic, Zhongheng Design, Jullyar, and Chaojie Precision.
Innovative drug stocks were repeatedly active, with TJPC up for 3 consecutive trading days, followed by Asymchem, Biosan, Pharmaron, HITECK, and Novus Therapeutics

- On March 31, A-shares experienced fluctuations, with the Shanghai index rising by 0.45%, while the ChiNext index fell by 0.41%.  
- Hong Kong stocks opened strong but narrowed their gains, with the Hang Seng index up 0.15%.  
- The bond market showed mixed results, and commodity futures mostly declined, although metals like silver and gold increased.

Wallstreetcn

SHENJIAN GUFEN

HITECK

SHUNHO STOCK

Ankai

SG AUTOMOTIVE GROUP

TJPC

Zhongtong Bus Holding Co.,LTD

YTCO

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

Pharmaron Lifts Revenue and Cash Flow in 2025 Despite Profit Dip

First Trust NYSE Arca Biotech Index Fd

Pharmaron Lifts Revenue and Cash Flow in 2025 Despite Profit Dip

Pharmaron announced its 2025 annual performance, with revenue of 14.095 billion RMB (same below), an increase of 14.8% year-on-year; gross profit of 4.857 billion RMB, an increase of 17.1%. It recorded a net profit of 1.664 billion RMB, a decline of 7.2%, with earnings per share of 0.9443 RMB. The final dividend remains at 0.20 RMB

"Performance" Pharmaron's annual net profit is 1.664 billion RMB, down 7.2%, with a final dividend of 20 cents

588250

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan. Pharmaron has reached a collaboration with Eli Lilly, which will invest 200 million USD to support the supply of Orforglipron in China. Eli Lilly plans to invest 3 billion USD over the next decade to expand its supply chain capacity in China. Goldman Sachs believes this collaboration reflects Eli Lilly's confidence in the Chinese market and expects Pharmaron to receive a positive market response

Pharmaron(300759.SZ)

Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)

BOCI Raises PHARMARON TP to HKD26, Maintains Buy

Pre-market trend | Pharmaron (3759.HK) is consolidating with reduced volume on April 29, initial bullish signals are emerging, is it building up for a rebound or a trap for the bulls?

Pharmaron rose over 8% in half a day, receiving a target price upgrade from Nomura

Shanghai Composite Index Volatile Up, Innovative Drugs and Auto Stocks Rally Mid-day, Commercial Aerospace Active, Hang Seng Tech Index Surges and Falls Back, Tech Stocks Diverge

Pharmaron Lifts Revenue and Cash Flow in 2025 Despite Profit Dip

"Performance" Pharmaron's annual net profit is 1.664 billion RMB, down 7.2%, with a final dividend of 20 cents

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan